HCV Clinical Trial
Official title:
An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt
Verified date | July 2021 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
Status | Completed |
Enrollment | 160 |
Est. completion date | August 1, 2016 |
Est. primary completion date | August 1, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Chronic hepatitis C, genotype 4-infection (hepatitis C virus [HCV] ribonucleic acid [RNA] level greater than 1,000 IU/mL at Screening) - Subjects must meet one of the following: - Treatment-naive: Subject has never received antiviral treatment for HCV infection OR - Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegylated-interferon [pegIFN]/RBV); - Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control - In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or Fibroscan - In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with Child-Pugh score less than or equal to 6 at Screening and confirmed absence of hepatocellular carcinoma Exclusion Criteria: - Females who are pregnant or breastfeeding - Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus antibody - HCV genotype performed during screening indicating unable to genotype or co-infection with any other HCV genotype - abnormal laboratory tests - self-reports current drinking more than 2 drinks per day - current enrollment in another investigational study - previous treatment with a direct acting antiviral agent (DAA) containing regimen - In substudy 1, evidence of liver cirrhosis - In substudy 2, evidence of current or past Child-Pugh B or C classification and confirmed presence of hepatocellular carcinoma |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. doi: 10.1016/S2468-1253(16)30002-4. Epub 2016 Jun 16. Erratum in: Lancet Gastroenterol Hepatol. 2016 Sep;1(1):e1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm | SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. | 12 weeks after last dose | |
Primary | Number of Participants With Adverse Events | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section. | Screening until 30 days after last dose | |
Secondary | Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm | On-treatment virologic failure was defined as quantifiable HCV RNA throughout the entire treatment period with at least 6 weeks of treatment, confirmed HCV RNA greater than the LLOQ after previously having unquantifiable HCV RNA, or a confirmed increase from nadir of at least one log10 in HCV RNA during treatment. | Up to 12 or 24 weeks after first dose | |
Secondary | Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm | Post-treatment relapse was defined as defined as confirmed HCV RNA > LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. | Up to 12 weeks after first dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05942937 -
National Prisons Hepatitis Education Project: Research Evaluation
|
N/A | |
Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
Recruiting |
NCT05794646 -
Community Intervention to Eliminate HCV Among People Who Use Drugs.
|
N/A | |
Completed |
NCT04971330 -
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
|
||
Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A | |
Active, not recruiting |
NCT03981445 -
Integrated HIV Prevention and HCV Care for PWID
|
N/A | |
Completed |
NCT02452814 -
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
|
N/A | |
Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
Not yet recruiting |
NCT06316739 -
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
|
N/A | |
Completed |
NCT02116543 -
TD-6450 MAD Study in HCV Infected Subjects
|
Phase 1 | |
Recruiting |
NCT05454579 -
The South-East Asian Transgender Health Cohort
|
||
Active, not recruiting |
NCT03221309 -
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
|
||
Completed |
NCT03801707 -
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03820102 -
Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
|
||
Completed |
NCT01074008 -
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
|
Phase 2 | |
Completed |
NCT05616598 -
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
|
Phase 2/Phase 3 | |
Recruiting |
NCT05854511 -
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
|
Phase 3 | |
Completed |
NCT03069001 -
Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV
|
Phase 4 | |
Completed |
NCT01842451 -
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
|
Phase 2 |